← Back to patent-cliff list
CAS 541-41-3
Carbonochloridic acid ethyl esterethyl carbonochloridateChloridocarbonic acid ethyl ester
Codes: (II)461018-4-a, EFAV-028, Tamsulosin Hydrochloride-088, SOLIF-002, SIME-015, IVAC-011, AZILS-006, S-pantoprazole sodium-057, LINE-012, (IVa)263642-7-a
Application context (from source-drug indications)
Waldenström macroglobulinaemiaIbrutinibChronic lymphocytic leukaemiaIbrutinibMantle cell lymphomaIbrutinibGraft-versus-host diseaseIbrutinibHIV infectionEfavirenz/Lamivudine/Tenofovir Disoproxil FumarateErectile dysfunctionTadalafil/TamsulosinBenign prostatic hyperplasiaTadalafil/TamsulosinLower urinary tract symptomsSolifenacin Succinate/Tamsulosin HydrochlorideBenign prostatic hyperplasiaSolifenacin Succinate/Tamsulosin HydrochlorideOveractive bladderSolifenacin Succinate/Tamsulosin HydrochlorideDrug-related adverse effects and reactionsSolifenacin Succinate/Tamsulosin HydrochlorideBladder neck obstructionSolifenacin Succinate/Tamsulosin HydrochlorideHepatitis CSimeprevir SodiumChronic hepatitis CSimeprevir SodiumMeaslesSimeprevir SodiumMycobacterium tuberculosis infectionSimeprevir SodiumCystic fibrosisIvacaftorChronic bronchitisIvacaftorChronic obstructive pulmonary diseaseIvacaftorSinusitisIvacaftorHypertensionAzilsartanEssential hypertensionAzilsartanType 2 diabetesAzilsartanObesityAzilsartanDiabetesAzilsartanBenign prostatic hyperplasiaDutasteride/Tamsulosin HydrochlorideGastro-oesophageal reflux diseaseS-pantoprazole sodiumPeptic ulcerS-pantoprazole sodiumHaemorrhageS-pantoprazole sodiumTrauma and injuryS-pantoprazole sodiumComaS-pantoprazole sodiumAspiration pneumoniaS-pantoprazole sodiumBenign prostatic hyperplasiaTamsulosin HydrochlorideUrinary tract infectionTamsulosin HydrochlorideUrinary retentionTamsulosin HydrochlorideInguinal herniaTamsulosin HydrochlorideVoiding dysfunctionTamsulosin HydrochlorideLower urinary tract symptomsTamsulosin HydrochlorideHIV infectionEfavirenzCreutzfeldt-Jakob diseaseEfavirenzAlzheimer's diseaseEfavirenzPancreatic cancerEfavirenzProstate cancerEfavirenzNon-Hodgkin lymphomaEfavirenzOveractive bladderSolifenacin SuccinateUrge incontinenceSolifenacin SuccinateUrinary tract diseaseSolifenacin Succinate非复杂性皮肤和皮肤结构感染LinezolidPneumoniaLinezolidComplicated skin and skin structure infectionLinezolidBacteraemiaLinezolidBacterial infectionLinezolidHealthcare-associated pneumoniaLinezolid分离性焦虑R-fluoxetineAnxietyR-fluoxetineAnxiety disorderR-fluoxetine
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Ibrutinib | Tier A — Act now | 2027 |
| Efavirenz/Lamivudine/Tenofovir Disoproxil Fumarate | Tier C — Watch / trade | - |
| Tadalafil/Tamsulosin | Tier C — Watch / trade | - |
| Solifenacin Succinate/Tamsulosin Hydrochloride | Tier C — Watch / trade | - |
| Simeprevir Sodium | Tier B — Position early | - |
| Ivacaftor | Tier B — Position early | - |
| Azilsartan | Tier C — Watch / trade | - |
| Dutasteride/Tamsulosin Hydrochloride | Tier C — Watch / trade | - |
| S-pantoprazole sodium | Tier C — Watch / trade | - |
| Tamsulosin Hydrochloride | Tier C — Watch / trade | - |
| Efavirenz | Tier B — Position early | - |
| Solifenacin Succinate | Tier B — Position early | - |
| Linezolid | Tier B — Position early | - |
| R-fluoxetine | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
4-(Phenyloxy)benzoic acid→Carbonochloridic acid ethyl ester→Ethyl 4-phenoxybenzoyl carbonate→1,1-Dicyanomethane→3-(4-Phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine→(4-Phenoxybenzoyl)malononitrile→[Chloro(4-phenoxyphenyl)methylene]malononitrile→3-Amino-4-cyano-5-(4-phenoxyphenyl)pyrazole→Formamidine acetate→3-Chloro-1H-pyrazolo[3,4-d]pyrimidin-4-amine→3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-amine→3-Iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine→4-Amino-1H-pyrazolo[3,4-d]pyrimidin-3-ylmethanesulfonate
ethynylcyclopropane→1-(2-amino-5-chlorophenyl)-2,2,2-trifluoroethanone hydrochloride→ethyl carbonochloridate→ethyl (4-chloro-2-(2,2,2-trifluoroacetyl)phenyl)carbamate→(1R,2R)-2-(benzyl(methyl)amino)-3-(tert-butoxy)-1-(4-nitrophenyl)propan-1-ol→(1R,2R)-2-(benzyl(methyl)amino)-1-(4-nitrophenyl)propane-1,3-diol→2-methylprop-1-ene
5-Acetyl-2-methoxybenzene-1-sulfonamide→2-(2-Ethoxyphenoxy)ethylamine→Tamsulosin Hydrochloride-085→(2R)-Hydroxy(phenyl)acetic acid 5-[(2R)-2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-methoxybenzene-1-sulfonamide→(S)-1-(tert-Butoxycarbonyl)pyrrolidine-2-carboxylic acid→Carbonochloridic acid ethyl ester→Ethoxycarbonyl 1-(tert-butoxycarbonyl)-L-prolinate→2-Methoxydibenzo[b,d]furan-3-amine→tert-Butyl (2S)-2-[(2-methoxydibenzo[b,d]furan-3-yl)carbamoyl]pyrrolidine-1-carboxylate→N-(2-Methoxydibenzo[b,d]furan-3-yl)-L-prolinamide
5-Acetyl-2-methoxybenzene-1-sulfonamide→2-(2-Ethoxyphenoxy)ethylamine→Tamsulosin Hydrochloride-085→(2R)-Hydroxy(phenyl)acetic acid 5-[(2R)-2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-methoxybenzene-1-sulfonamide→(S)-1-(tert-Butoxycarbonyl)pyrrolidine-2-carboxylic acid→Carbonochloridic acid ethyl ester→Ethoxycarbonyl 1-(tert-butoxycarbonyl)-L-prolinate→2-Methoxydibenzo[b,d]furan-3-amine→tert-Butyl (2S)-2-[(2-methoxydibenzo[b,d]furan-3-yl)carbamoyl]pyrrolidine-1-carboxylate→N-(2-Methoxydibenzo[b,d]furan-3-yl)-L-prolinamide
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.